# Samsung Biologics Launches $1.81B All-Cash Tender Offer to Acquire Swiss Peptide CDMO PolyPeptide

> ma · REPORTED · 2026-07-20

Samsung Biologics announced an all-cash tender offer of CHF 44.31 per share, totaling approximately CHF 1.46 billion ($1.81 billion), to acquire Swiss contract drugmaker PolyPeptide, with PolyPeptide's board unanimously recommending shareholders accept the offer. The acquisition expands Samsung Biologics into peptide-based therapeutics manufacturing including fast-growing GLP-1 drugs for obesity and diabetes.

About Samsung Biologics: Samsung Biologics is a South Korean contract development and manufacturing organization (CDMO) that provides large-scale biologics drug substance and drug product manufacturing services to global pharmaceutical companies.

- Company: Samsung Biologics
- Sector: biotech
- Primary source: https://www.bioprocessintl.com/deal-making/samsung-biologics-extends-1-8bn-acquisition-offer-to-glp-1-maker-polypeptide

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.